PNP Pharmaceuticals contracted as exclusive global manufacturer of Fero Industries' Sucanon

Fero Industries, Inc. (OTCQB: FROI) (the "Company") is pleased to announce that it has contracted PNP Pharmaceuticals Inc. as the exclusive global manufacturer of Sucanon®, an oral treatment for type-2 diabetes.  

"The addition of PNP Pharmaceuticals as the exclusive Sucanon® manufacturer will immediately allow us to expand our supply capabilities to meet current demands and satisfy the anticipated increase in product volume required as we expand Sucanon® into new territories around the globe," said Mr. Luis Lopez, Chief Operating Officer of Fero Industries.  "During this expansion period, maintaining absolute quality and formulation control is essential to our success.  PNP's worldwide experience and dedication to excellence will ensure that we achieve these goals."  

PNP Pharmaceuticals Inc. (PNP) is a leading Canadian contract manufacturer of pharmaceuticals, nutraceuticals, and other OTC products for export to markets worldwide.  Founded in 1999, PNP has the expertise and high-volume production capabilities to formulate, blend, and package any form of Sucanon® (capsule, tablet, or bulk package for overseas transport) to the highest industry standards.  PNP operates an ultra-modern 48,000 square foot manufacturing facility that meets or exceeds all "Good Manufacturing Practice" guidelines set forth by the US Food and Drug Administration (FDA) and World Health Organization (WHO).  This facility was the first ever location in Canada to be issued a Natural Health Products Directorate (NHPD) site license.  PNP is also Quality Management Systems certified ISO 9001:2000.